NewsFeed Voices Science Insight Innovation
December, 2025
December 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Wolfgang Miesbach – New Hope for Hereditary Haemorrhagic Telangiectasia: First Trial Results for Engasertib Published in NEJM
Wolfgang Miesbach/LinkedIn
Dec 4, 2025, 03:26

Wolfgang Miesbach – New Hope for Hereditary Haemorrhagic Telangiectasia: First Trial Results for Engasertib Published in NEJM

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

“New Hope for Hereditary Haemorrhagic Telangiectasia: First Trial Results for Engasertib Published in NEJM. A groundbreaking proof-of-concept trial has just been published on a novel oral therapy specifically developed for hereditary haemorrhagic telangiectasia (HHT) – a disease that has no licensed treatments worldwide despite affecting approximately 1 in 3,800 individuals. Current options – antifibrinolytics, invasive procedures, or off-label bevacizumab, thalidomide and pomalidomide – are inadequate, often inaccessible, and carry significant burden.

The Disease Burden
HHT is the second most common inherited bleeding disorder globally, yet it remains significantly undertreated. Patients suffer from:
– Recurrent, severe epistaxis (nosebleeds) in >90% of cases, often starting in childhood
– Chronic anaemia requiring repeated iron infusions and transfusions
– Arteriovenous malformations affecting lungs, liver, brain and GI tract
– Profound impact on quality of life, with associated depression and anxiety

The Innovation
Engasertib (VAD044) is an oral, once-daily, allosteric AKT inhibitor developed specifically for HHT. The drug works by addressing the underlying pathophysiology – mutations in the ALK1 signalling pathway lead to AKT overactivation, driving telangiectasia formation.

The Trial Results
This multicentre, double-blind, placebo-controlled trial enrolled 75 patients randomised 1:1:1 to engasertib 30mg, engasertib 40mg, or placebo for 12 weeks:

– Safety: Excellent tolerability profile
Most common adverse events: mild-to-moderate rash (42% at 40mg dose) and hyperglycaemia (12%), both reversible
Serious adverse events similar across all groups
Notably favourable compared to existing off-label therapies (bevacizumab, pomalidomide)

– Efficacy signals (40mg dose):
41.4% reduction in epistaxis duration
27.8% reduction in epistaxis frequency
1.6-point decrease in Epistaxis Severity Score
61% of patients reported feeling “much better” on Patient Global Impression of Change

– The open-label extension (up to 12 months) showed even more impressive results:
65.6% reduction in epistaxis duration
54.9% reduction in frequency
Mean increase of 8.7 epistaxis-free days per month

Why This Matters
For the first time, we have a purpose-built therapy for HHT with:

  • Once-daily oral administration
  • Manageable safety profile
  • Dose-dependent efficacy
  • Sustained benefit with continued treatment
  • Potential for regulatory approval and global accessibility

This represents a paradigm shift from repurposed cancer drugs with unknown optimal dosing to a rationally designed therapy addressing the underlying disease mechanism.

Congratulations to Dr Hanny Al-Samkari and the entire international research team on this important milestone!”

Ttile:Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia

Authors: Hanny Al-Samkari, Josefien Hessels, Antoni Riera-Mestre, Sophie Dupuis-Girod, Thibaut Van Zele, Vicente Gómez del Olmo, Pamela G. Hodges, Hans-Jurgen Mager

Wolfgang Miesbach - New Hope for Hereditary Haemorrhagic Telangiectasia: First Trial Results for Engasertib Published in NEJM

Access the Original Research.

Elevate your knowledge with Hemostasis Today.

ALK1 Antoni Riera-Mestre engasertib Haemorrhagic Telangiectasia Hanny Al-Samkari Hans-Jurgen Mager Health Hematology Hemostasis Hemostasis Today HHT Josefien Hessels Medicine NEJM Pamela G. Hodges Sophie Dupuis-Girod Thibaut Van Zele VAD044 Vicente Gómez del Olmo Wolfgang Miesbach
NewsFeed